Name | Phenazopyridine hydrochloride |
Description | Phenazopyridine hydrochloride (Pyridium) is used orally as a urinary tract analgesic. Side effects of phenazopyridine hydrochloride administration can include nausea, interference with the oxygen-carrying capacity of red blood cells (methemoglobinemia), hemolytic anemia as well as renal and hepatic toxicity. It is reasonably anticipated to be a human carcinogen. |
In vitro | Phenazopyridine directly inhibits the mechanical sensitivity of Aδ-fibers in the bladders of normal rats. |
In vivo | Phenazopyridine enhances cell viability, strengthens neuronal cell differentiation, synchronizes the state of cell differentiation, and reduces the number of non-neuronal and undifferentiated cells. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 10 mg/mL (40.05 mM), Sonication is recommended.
|
Keywords | Phenazopyridine hydrochloride | Inhibitor | Phenazopyridine | inhibit | Phenazopyridine Hydrochloride |
Inhibitors Related | Phenytoin sodium | Lidocaine | Valproic Acid | Lidocaine hydrochloride | L-Aspartic aicd sodium | Mebeverine hydrochloride | Amitriptyline hydrochloride | Riluzole | Benzocaine | Nefopam hydrochloride |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |